In England, trastuzumab deruxtecan was accepted by the National Institute for Health and Care Excellence (NICE) for use within the Cancer Drugs Fund in December 2022 as a treatment option for HER2-positive unresectable or metastatic breast cancer after at least 1 prior anti-HER2 ...
FDA grants regular approval to fam-trastuzumab deruxtecan-nxki for breast cancer. News release. FDA. May 4, 2022. Accessed February 24, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs Enhertu approved in the EU for patients with HER2-positive metastatic breast ca...
Treatment options for patients with metastatic breast cancer are severely limited and ultimately rely on palliative care representing an unmet clinical need. Pr...
The extent to which a plant-based diet lowers the serum levels of amino acids in patients with cancer is unclear. Methods Patients with metastatic breast cancer (n = 17) were enrolled in a clinical trial with an ad libitum whole food, plant-based diet for 8 weeks without calorie or ...
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Save November 30, 2023 5:00 pm ET Acceptance based on results from ...
FDA Grants Fast Track Designation to Deltacel Plus Radiation for Pretreated Metastatic NSCLC Fast track designation has been granted by the FDA to Deltacel (KB-GDT-01) with low-dose radiation therapy to potentially treat patients with metastatic non–small cell lung cancer (NSCLC...
The FDA granted priority review to elacestrant for ER-positive, HER2-negative advanced or metastatic breast cancer.Elacestrant (Menarini Group/Stemline Therapeutics) is a selective estrogen receptor degrader (SERD).
et al. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer. Breast Cancer Res 26, 13 (2024). https://doi.org/10.1186/s13058-024-01768-y Download citation Received30 May 2023 Accepted09 ...
ivNational Cancer Institute. SEER Cancer Stat Facts: Cervical Cancer. 2023.https://seer.cancer.gov/statfacts/html/cervix.html vMcLachlan J, Boussios S, Okines A, et al. The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. Clin Oncol (R ...
A Correction to this article was published on 25 July 2023 This article has been updatedAbstract The lack of approved targeted therapies highlights the need for new treatments for triple-negative breast cancer (TNBC) patients. Interleukin-3 (IL-3) acts as an autocrine factor for tumor–endothelia...